Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oncolys BioPharma's Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円-910.04 Mil. Therefore, Oncolys BioPharma's EV-to-EBIT ratio for today is -78.07.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Oncolys BioPharma's Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円-909.99 Mil. Therefore, Oncolys BioPharma's EV-to-EBITDA ratio for today is -78.07.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Oncolys BioPharma's Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円31.64 Mil. Therefore, Oncolys BioPharma's EV-to-Revenue ratio for today is 2,245.69.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Oncolys BioPharma (TSE:4588) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-910.04 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-909.99 Mil.
Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円31.64 Mil.
Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil.
Oncolys BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma Enterprise Value Related Terms
Oncolys BioPharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4588 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Oncolys BioPharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Oncolys BioPharma's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of 円71,044.57 Mil mean?
Oncolys BioPharma (TSE:4588) has a Enterprise Value of 円71,044.57 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Enterprise Value too high?
Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Enterprise Value compare to VRTX and REGN?
Oncolys BioPharma's Enterprise Value of 円71,044.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current Enterprise Value is 円71,044.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,522.00 — trading 594.1% above its estimated fair value. The current Enterprise Value is 円71,044.57 Mil. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Enterprise Value is 円71,044.57 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,522.00 is trading 594.1% above its estimated GF Value™ of 円363.33.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Enterprise Value: 円71,044.57 Mil
GF Value™: 円363.33 vs. price of 円2,522.00 (594.1% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
